MIR8088: A Potential Drug Target and Biomarker for Melanoma (G102466880)

MIR8088: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a type of skin cancer that is characterized by the rapid growth of skin cells that produce melanin. It is a highly aggressive and potentially deadly form of cancer, with a five-year survival rate of only 15%. Despite advances in treatment, the standard treatment for melanoma remains a cutting-edge approach, and there is a high demand for new and more effective therapies.

One potential drug target for melanoma is MIR8088, a microRNA (miRNA) that has been shown to play a role in the development and progression of melanoma. MIR8088 is a non-coding RNA molecule that is derived from the DNA of the genomelanin gene. In recent years, researchers have identified MIR8088 as a potential drug target for melanoma due to its unique structure and its involvement in the development of this disease.

The discovery of MIR8088 as a potential drug target for melanoma was made through a study conducted by a team of researchers led by Dr. Xujiong Ye at the University of California, San Francisco (UCSF). The researchers used a variety of techniques, including RNA sequencing and biochemical assays, to identify MIR8088 as a miRNA that was expressed in melanoma cells and was downregulated in non-melanoma skin samples.

To determine the potential clinical applications of MIR8088 as a drug target, the researchers conducted a series of experiments to investigate its effects on melanoma cell growth and metastasis. They found that MIR8088 was effective in inhibiting the growth of melanoma cells and inhibiting the formation of new blood vessels that are a hallmark of melanoma progression. The researchers also found that MIR8088 was effective in slowing down the metastasis of melanoma cells to other organs, such as the lungs and the brain.

In addition to its potential as a drug target, MIR8088 has also been identified as a potential biomarker for melanoma. The researchers found that MIR8088 was downregulated in melanoma tissues, and that higher levels of MIR8088 were associated with poorer prognosis in melanoma patients. This suggests that MIR8088 may be a useful biomarker for tracking the progression of melanoma and for identifying individuals who are at risk for this deadly form of cancer.

The identification of MIR8088 as a potential drug target and biomarker for melanoma is an exciting development in the fight against this aggressive and deadly form of cancer. Further research is needed to determine the exact mechanisms by which MIR8088 exerts its effects on melanoma and to develop effective treatments. However, the potential of MIR8088 as a drug target and biomarker for melanoma is a promising area of research that could lead to new and more effective therapies for this devastating form of cancer.

Protein Name: MicroRNA 8088

The "MIR8088 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR8088 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2